0
Skip to Content
NMD Pharma
Home
About NMD Pharma
Management team
Our team
Board
Founders
Pipeline
Science
Neuromuscular diseases
Patient insights
Scientific publications
Information for patients
Spinal Muscular Atrophy
Myasthenia Gravis
Charcot-Marie-Tooth
Press releases
Events
Other news
Investors
Your career
Find your job
Contact
NMD Pharma
Home
About NMD Pharma
Management team
Our team
Board
Founders
Pipeline
Science
Neuromuscular diseases
Patient insights
Scientific publications
Information for patients
Spinal Muscular Atrophy
Myasthenia Gravis
Charcot-Marie-Tooth
Press releases
Events
Other news
Investors
Your career
Find your job
Contact
Home
Folder: About
Back
About NMD Pharma
Management team
Our team
Board
Founders
Folder: R&D
Back
Pipeline
Science
Neuromuscular diseases
Patient insights
Scientific publications
Folder: Patients & Clinical Trials
Back
Information for patients
Spinal Muscular Atrophy
Myasthenia Gravis
Charcot-Marie-Tooth
Folder: News
Back
Press releases
Events
Other news
Investors
Folder: Careers
Back
Your career
Find your job
Contact
NMD Pharma raises €38M (USD 47 Million) SERIES A</a> Financing
Press release Stine Krag Brunvold 3/23/18 Press release Stine Krag Brunvold 3/23/18

NMD Pharma raises €38M (USD 47 Million) SERIES A Financing

It all begins with an idea.

Read More
Newer Posts

NMD PHARMA A/S, CVR No. 36899069

Cookie Policy Terms of Use Privacy Policy US Expanded Access Policy

Follow us
LinkedIn X Facebook Instagram